The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).
 
Elisa A. Rozeman
No Relationships to Disclose
 
Yanina Jansen
Travel, Accommodations, Expenses - Novartis
 
MarnixMarnix Heimen Geukes Foppen
No Relationships to Disclose
 
Max Schreuer
Travel, Accommodations, Expenses - Astellas Pharma
 
Sofie Wilgenhof
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
 
Johannes V. Van Thienen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)
 
Christian U. Blank
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - MSD; Pfizer; Roche/Genentech
 
Bart Neyns
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst); Pfizer (Inst)